Advancing Hope: AFTD Staff Attend NORD Breakthrough Summit in Washington, DC

Graphic: Advancing Hope - AFTD Staff Attend NORD Breakthrough Summit in Washington DC

Shana Dodge, PhD, AFTD’s Director of Research Engagement and Meghan Buzby, MBA, AFTD’s Director of Advocacy and Volunteer Engagement attended the National Organization for Rare Disorders (NORD) Breakthrough Summit, held October 20-22 in Washington, DC. NORD is an advocacy organization dedicated to individuals with rare diseases and is committed to the identification, treatment, and cure…

Read More

GemVax & KAEL Announces Results from Phase 2a Clinical Trial for PSP

Title: GemVax & KAEL Announces Results from Phase 2a Clinical Trial for PSP Background: A woman looks through a microscope

South Korean biopharmaceutical company GemVax & Kael announced in late October the results from its phase 2a clinical trial evaluating a drug for PSP. While the drug failed to show significant efficacy, the results showed enough promise that the company is proceeding to phase 3 trials. PSP, or progressive supranuclear palsy, is an FTD disorder…

Read More

Dear HelpLine: Navigating Travel During the Holidays

Text: Dear HelpLine - Navigating Travel During the Holidays Background: A woman fastens straps inside of a packed suitcase.

Dear HelpLine, I am thinking of traveling to see family this year for the holidays, but this would be the first time taking my wife since she was diagnosed with FTD 2 years ago.  Is there anything you can share with me about traveling with someone with FTD? For many people, the holiday season is…

Read More

A Conversation with Alector’s Vice President of Clinical Development

Text: A conversation with alector's vice president of clinical development. Background: Photo of Lawrence Carter, AFTD and Alector logos

Earlier this year, the biopharmaceutical company Alector announced that the U.S. Food and Drug Administration (FDA) had granted a “breakthrough therapy designation” to latozinemab, the company’s investigational drug designed to address FTD caused by a variant in the GRN gene. The special designation enables expedited regulatory review of therapies intended to treat serious conditions. A…

Read More

Vesper Bio Announces Successful Completion of Phase 1 Study for Potentially Disease-Modifying Treatment for FTD-GRN

Text: Vesper Bio Announces Successful Completion of Phase 1 Study for Potentially Disease-Modifying Treatment for FTD-GRN Background: A laboratory, with a computer displaying PET scan results.

Biotechnology company Vesper Bio announced in early September that the phase 1 clinical trial for its potentially disease-modifying treatment for FTD-GRN has successfully concluded. The company noted data from the trial demonstrated excellent safety and tolerability of the orally administered drug VES001. In FTD caused by an inherited GRN mutation, the production of the essential…

Read More

November 24, 2024: In-Person Meet & Greet in Manchester, NH

Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD Ambassador Shirley Gordon and Kevin Rhodes, co-chair of the AFTD Persons with FTD Advisory Council. The event will take place from 7:30 a.m. – 12:00 p.m. on November 24 at St. Catherine of Siena…

Read More

In-Person Meet & Greet in Manchester, NH

Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD Ambassador Shirley Gordon and Kevin Rhodes, co-chair of the AFTD Persons with FTD Advisory Council. RSVP for this event by emailing sgordon@theaftd.org. To learn more, download this flyer.

Read More